Akademik Veri Yönetim Sistemi
ANADOLU KLİNİĞİ TIP BİLİMLERİ DERGİSİ, cilt.26, sa.1, ss.45-53, 2021 (Hakemli Dergi)
Aim: Nesfatin -1 is a novel peptide which is defined as satiety peptide with an anorexigenic action. Studies have shown its association with metabolic syndrome and insulin resistance. With this study, we sought to establish the association between clinicopathologic characteristics of patients with biopsy-diagnosed non-alcoholic fatty liver disease (NAFLD) and Nesfatin-1. Materials and Methods: Serum Nesfatin-1 levels were measured using the enzyme-linked immunosorbent assay in 59 patients with histologically diagnosed NAFLD and a control group comprising 32 healthy subjects. Results: Serum Nesfatin-1 level did not significantly differ between patients with NAFLD and control group (p<0.170). Simple correlation analysis showed that nesfatin-1 levels decreased as body mass index increased (p=0.043) and nesfatin-1 values increased in proportion to elevations in AST (p=0.05). A multiple regression model constructed for assessment showed that while portal inflammation (B=10.767, p=0.007), body mass index score (B=-0.510, p<0.001) and HDL cholesterol (B=-0.208, p<0.001) had a negative association with nesfatin-1, age (B=0.120, p=0.031), sex (lower levels among males versus females) (B=-40.897, p<0.001), systolic blood pressure (B=0.063, P=0.050) and AST (B=0.033, p=0.019) had a positive and linear significant association with nesfatin-1. Conclusion: In conclusion, the findings point out that serum nesfatin-1 level may be an independent predictor of portal inflammation in NAFLD.